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Zusammenfassung  
 
Die körpereigene Fähigkeit zur Regeneration von Gelenkknorpel nach traumatischer 
oder degenerativer Schädigung ist stark eingeschränkt. Mesenchymale Stammzellen 
(MSCs) sind eine vielversprechende Quelle zur Regeneration von mesenchymalem 
Gewebe wie etwa hyalinem Knorpel. MSCs haben das Potential zukünftig autologe 
Chondrozyten in der Therapie von Knorpeldefekten zu ersetzen. Es besteht die 
Chance, dass die pluripotenten Zellen die embryonale Entwicklung von 
Gelenkknorpelzellen während der Skelettformation nachvollziehen können.  
Jedoch exprimieren in vitro chondrogen differenzierten MSCs hypertrophe Marker wie 
Kollagen X und Matrixmetalloproteinase 13 (MMP13). Dies zeigt, dass die 
Chondrogenese der MSCs nicht auf einer für Gelenkknorpelzellen üblichen 
Entwicklungsstufe endet, sondern spontan weiterläuft hin zu einem hypertrophen 
Stadium, wie es für die Chondrozyten der Wachstumsfuge während der enchondralen 
Ossifikation typisch ist. Da Hypertrophie jedoch langfristig in Apoptose und Ossifikation 
mündet, schränkt dieser Umstand den Einsatz von MSCs in tissue engineering von 
Gelenkknorpel maßgeblich ein. 
In der Skelettentwicklung übt der Retinsäure - Rezeptor (RAR) – Signalweg einen 
wichtigen Einfluss auf die Entwicklung von mesenchymalen Vorläuferzellen aus. 
Während Retinoide die Chondrogenese hemmen und die Hypertrophie in der 
Wachstumsfuge fördern, scheint die Unterdrückung der RAR-Wirkung für frühe 
chondrogene Differenzierungsstufen notwendig zu sein. Daher haben wir die 
Hypothese aufgestellt, dass die Behandlung von chondrogen differenzierenden 
Chondrozyten mit dem inversen RAR-Agonisten BMS 204,493 die Hypertrophie 
hemmen kann. Um diese Hypothese zu überprüfen haben wir die Wirkung von BMS 
auf humane MSCs auf histologischer, genetischer sowie Protein-Ebene untersucht. 
Hypertrophie wurde in chondrogen vordifferenzierten MSCs durch den Entzug von 
transforming growth factor β (TGFβ) und Dexamethason sowie durch den Einfluss von 
bone morphogenic protein 4 (BMP4) induziert. Die Behandlung mit BMS bewirkte nach 
Einleitung der Hypertrophie eine Hemmung der hypertrophen Differenzierung der 
hMSCs, deutlich zu erkennen an der geringeren Zellgröße, ALP-Aktivität und Kollagen 
X - Genexpression sowie - Produktion. Die Wirkung von BMS war abhängig vom 
Zeitpunkt der Applikation und am stärksten ausgeprägt bei Anwendung in der frühen 
Phase der Differenzierung. Die Möglichkeit die Entwicklung von MSCs durch die 
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Hemmung des RAR-Signalwegs durch BMS zu modifizieren dürfte für die Produktion 
von stabilem Gewebe zur Regeneration von Gelenkknorpel hilfreich sein. 
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Abstract 
 
Cartilage’s potential to regenerate itself after damage has occurred is very limited. 
Mesenchymal stem cells (MSCs) are a promising source for the regeneration of 
mesenchymal tissue such as hyaline cartilage. MSCs may have the potential to replace 
autologous chondrocytes in the therapy of cartilage defects and to provide even better 
results. Furthermore, there is a chance that they are able to recapitulate the embryonic 
lineage transitions originally involved in the formation of joint tissue. 
In vitro chondrogenically differentiating MSCs have the tendency to undergo 
hypertrophy mirroring the fate of transient ‘chondrocytes’ in the growth plate. As 
hypertrophy would result in ossification this fact limits the use of MSCs for cartilage 
tissue engineering applications. During limb development retinoic acid receptor (RAR) 
signaling exerts an important influence on cell fate of mesenchymal progenitors. While 
retinoids attenuate chondrogenesis and foster hypertrophy in the growth plate, 
suppression of RAR signaling seems to be required for early chondrogenic 
differentiation. Therefore, we hypothesized that treatment of chondrogenically 
differentiating human MSCs (hMSCs) with the RAR inverse agonist, BMS204,493, will 
attenuate hypertrophy. To test this hypothesis, we analyzed the effect of BMS on 
hMSCs on histological, genetical and protein level. Hypertrophy was induced in 
chondrogenic pre-cultured MSC pellets by withdrawal of transforming growth factor β 
(TGFβ) and dexamethasone and addition of bone morphogenetic protein 4 (BMP4). 
Upon induction of hypertrophy, BMS treatment reduced hypertrophic conversion in 
hMSCs, clearly shown by decreased cell size, ALP activity and collagen type X gene 
expression and deposition. BMS effects were dependent on the time point of 
application and strongest after early treatment during chondrogenic pre-cultivation. 
The possibility to modify hypertrophic cartilage via attenuation of RAR signaling by 
BMS may be helpful in producing stable engineered tissue for cartilage regeneration. 
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1 Introduction 
 
1.1  Cartilage 
 
Cartilage is a highly specialized connective tissue that fulfills several functions in the 
human body. Most important is its ability to withstand mechanical load without getting 
deformed. Cartilage consists of a single type of differentiated cells, the chondrocytes. 
The chondrocytes form small isogenic cell groups called chondrons, which are 
surrounded by a rich extracellular matrix (ECM). The ECM is built, maintained and 
remodeled by the chondrocytes themselves. The ECM mainly contains two 
components: An organized network of collagen fibers, basically collagen II but also 
collagen type I, IX and XI, and an amorphous substance of proteoglycans (mostly 
aggrecan) and glycosaminoglycans (mostly hyaluronan). Aggrecan and hyaluronan 
form large aggregates and because of their negative loading due to phosphorylation 
they have the capability to bind water. This results in the pressure elasticity with high 
resistance to stress and strain and therefore in the inevitable biomechanical properties 
[1]–[3].  
 
 
FIGURE 1 Composition of cartilage ECM: Combined functions of collagen fibers and 
proteoglycans. Following the negative load of proteoglycans water flows into the cartilage. Due to the 
swelling pressure tension is applied on the framework of collagen fibers. The interaction between the 
structures allows the characteristic biochemical properties of the cartilage 
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Depending on the kind of cartilage the ECM differs in its composition. There are neither 
nerves nor lymphatic vessels nor blood vessels in cartilage, so it has to be completely 
supplied with nutrients by diffusion from the capillaries of the perichondrium or the 
synovial fluid in the articular cavity. Thus, chondrocytes show just a low metabolic 
activity and depend primarily on anaerobic metabolism [1]–[3]. 
Because of the various functional needs three different forms of cartilage have 
developed: 
 
1.1.1 Elastic cartilage 
 
Elastic cartilage can be found in the external ear, epiglottis and larynx. It adds strength 
and elasticity to these structures to maintain their shape. Elastic cartilage is surrounded 
by a perichondrium, a dense connective tissue with an outer fibrous layer of fibroblasts 
that produce collagenous fibers and an inner chondrogenic layer of undifferentiated 
progenitor cells that can differentiate to chondroblasts and chondrocytes. The 
chondrocytes of the elastic cartilage are embedded in an extracellular matrix 
containing a network of elastic fibers [2]–[5].	 
 
1.1.2 Fibrocartilage 
 
The strongest kind of cartilage is the fibrocartilage. It is a mixture between cartilaginous 
tissue and a fibrous tissue composed of dense collagen fibers. As a specialty it 
contains also collagen type I apart from collagen type II, which is usually more often to 
be found in cartilage. Fibrocartilage has no perichondrium. It is part of the intervertebral 
discs and the joint capsule and forms the junction between tendons and bones [2]–[4].	
 
1.1.3 Hyaline cartilage 
 
The most abundant form of cartilage is the hyaline cartilage. As “hyalos” is the Greek 
word for glassy, hyaline cartilage has a milky, transparent appearance. It is mainly 
located in the joints but also in rips and the human airways such as nose, larynx, 
trachea and bronchi. During enchondral ossification in skeletogenesis and in the 
growth plate of long bones it acts as a precursor of the bone. As the main parts of the 
extracellular collagen are fine collagen type II fibers, it’s the weakest kind of cartilage. 
Beyond the joint cavity hyaline cartilage is surrounded by perichondrium [1]–[4], [6].	
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1.1.4 Articular cartilage 
 
Articular cartilage is a special form of hyaline cartilage that covers the surface of 
diarthrodial joints. Its fundamental function is to feature proper conditions for 
articulation as an interface between two articulating bones, which means after all to 
reduce the friction to a minimum and to provide biomechanical stability as it acts as a 
buffer and thus protects the subchondral bone from mechanical impaction. The smooth 
hyaline cartilage without a perichondrium in combination with the synovia, a fluid rich 
of hyaluronan, as a lubricant is especially well suited for this job.  
Articular cartilage is divided into different zones depending on the structure of the ECM 
components and on the distinct morphologies and orientation of chondrocytes. Cells 
in different layers express markers that are characteristic of each zone. The layered 
architecture of the articular cartilage is the result of mechanical forces applied to the 
tissue during maturation and can be segmented into the following zones: the superficial 
or tangential zone, the middle or transitional zone, the deep or radial zone, and the 
calcified zone. The ECM of the superficial zone mainly consists of thin collagen fibers 
that are lying parallel to the surface. The content of proteoglycans is low, which leads 
to a higher tissue permeability compared to the residual cartilage. The flattened 
chondrocytes in this area are accountable for appositional cartilage growth and are 
orientated parallel to the surface, closely associated to the collagen fibers. The middle 
zone features a lower cell density and the chondrocytes are configured roundly. The 
ECM in this layer is basically composed of type II collagen, which is organized into 
arcades, and proteoglycans in the highest concentration of all zones. The cells and 
collagen fibers of the deep zone and the calcified zone are arranged vertically to the 
subchondral bone. The cell density is lower than that in the other zones, while the 
proteoglycan content is relatively high. The presence of collagen X and hydroxyapatite 
in this area indicates chondrocyte maturation and calcification at the transition from 
cartilage to subchondral bone. The calcified zone functions as an interface between 
bone and cartilage to reduce the existing mechanical gradient [1], [3], [7]. 
 
 
 
 
 
	 4	
 
 
 
With its particular architecture of collagen fibrils articular cartilage is moreover capable 
of transmitting punctual loads equally to the subjacent bone area. This gives it a high 
resistance to sheer, tensile and compressive forces. The collagen fibrils, mainly 
collagen II with small additions of collagen IX and XI, are arranged arched like arcades 
and are anchored in the bone on both ends. Thus, mechanical pressure spreads over 
the whole collagen arch and in the sum of the fibrils this effect leads to an equal 
distribution of punctual stress to the subchondral bone. 
Further articular cartilage simply acts as an effective shock absorber within the joint. 
This is based on its great content of proteoglycan (PG) aggregates, which are built off 
aggrecan and the electronegative glycosaminoglycans (GAG) hyaluronan, chondroitin 
sulfate and keratan sulfate. These aggregates are connected to the collagen fibrils. 
Because of the rejection of their negative loadings and the ability to incorporate water 
the PG aggregates would expand enormously but in the cartilage they are hold back 
by the tense collagen fibrils [FUGURE 1]. This allows barely a fifth of their possible 
dimension and results in the remarkable stability and pressure elasticity of the 
cartilage. The PGs can be compressed a bit indeed, but after decompression they 
FIGURE 2 Schematic representation of the multi-zonal structure of articular cartilage showing 
the collagen and cell orientation. Collagen fibers are arranged in an arched pattern (dashed line). 
Application of compressive and shear forces to the articular surface (red arrows). 
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immediately expand to that limit given by the collagen fibrils, such as small elastic 
springs. The compression and decompression are accompanied by a corresponding 
flow of water into or out of the cartilage. But the low permeability of articular cartilage 
prevents the tissue from losing the fluid too quickly, which would reduce the shock 
absorbing effect [1]–[3], [6]. Apart from the biochemical skills cartilage also fulfills a 
paracrine function. Chondrocytes in articular cartilage influence each other through 
paracrine regulatory factors including TGFb superfamily, Indian hedgehog homolog 
(IHH), parathyroid hormone related proteins (PTHrP) and Wnts. Thus articular 
chondrocytes are controlled by their environment not to undergo hypertrophy and to 
keep a stable chondrogenic state [8], [9]. Consequently disturbances of this paracrine 
signaling lead to abnormal articular cartilage development [10]–[12]. By comparison in 
growth plate cartilage IHH and PTHrP are secreted in the resting zone and the 
proliferation zone as well to inhibit hypertrophy and stimulate proliferation. But 
chondrocytes of the hypertrophic zone produce bone morphogenic proteins (BMPs) 
and Wnts to initiate hypertrophic differentiation of adjacent proliferating chondrocytes 
[8]. 
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1.2 Acute cartilage injury 
 
Injuries of the articular cartilage and the calcified chondral-subchondral bone region 
can have various possible causes and shapes.  
According to the ICRS Hyaline Cartilage Lesion Classification System they can be 
classified into five grades [13]:  
 
Grade 0:  Normal cartilage 
Grade 1:  Superficial lesions. Soft indentation and/or superficial fissures and cracks 
Grade 2:  Lesions extending down to <50% of cartilage depth 
Grade 3:  Cartilage defects extending down to >50% of cartilage depth as well as 
down to calcified layer and down to but not through the subchondral 
bone. Blisters are included in this grade. 
Grade 4:  Osteochondral injuries, lesions extending just through the subchondral 
bone plate or deeper defects down into trabecular bone. 
 
Articular injuries can be generated by a direct blunt trauma or an indirect or torsional 
loading. Blunt traumas could be hitting the joint with an optional object or falling on 
hard ground. Examples of indirect and torsional stress are leverage through a strike to 
a limb or an intense torsion of a loaded joint for example in sports like skiing or soccer. 
Generally speaking these are situations that frequently occur in sports and everyday 
live [7].  
The mentioned injuries cause joint pain and limited range of motion and can evolve 
into osteoarthritis. Osteoarthritis is a degenerative joint disease that is characterized 
by a loss of articular cartilage and a degeneration of the subchondral bone as it lacks 
the protective cartilage layer. 
Apart from the mentioned situations joint instability, insufficient joint or muscle 
innervation, a deficit in muscle strength or endurance, or a past joint surgery increase 
the risk of a degenerative joint disease as well. Even a successful anterior crucial 
ligament (ACL) reconstruction comes along with an increased risk for osteoarthritis 
[14]. As the disease can be traced back to a certain cause it’s called secondary 
osteoarthritis. However osteoarthritis may also develop without an initial cause as a 
primary osteoarthritis for example because of the normal proceeding degeneration 
during the aging or long-term physical work [15]. 
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To achieve the best possible results in treatment of osteoarthritis it is important to 
identify risk factors, which also include overweight, genetic predisposition and 
increased physical activity, and first symptoms in an early stage of the disease. 
Especially in early osteoarthritis, when clear clinical and radiographic signs may be 
limited, there might still be regenerative capability of the articular cartilage [16].  
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1.3 Repair capacity of articular damage 
 
In general cartilage’s potential to regenerate itself after damage has occurred is very 
limited. But if the injury restricts to the macromolecular framework such as disruption 
of collagen fibrils, the chondrocytes can react to the changed matrix composition with 
an increased production of new matrix molecules. Thus, chondrocytes are able to 
repair small defects to a certain degree. However, at the latest when the lesions reach 
macroscopically dimensions like chondral ruptures, flaps and tears the self-repair 
capacity of cartilage is exhausted. Although surrounding chondrocytes respond by 
proliferating and synthesizing extracellular matrix, they are not capable of filling the 
whole defect [7].  
When it comes to the point, that subchondral bone is injured, the initial situation is 
another one. Blood from the bone marrow enters the injury site and fills the defect with 
a clot of fibrin and platelets. Platelets and bone matrix release growth factors and 
cytokines such as transforming growth factor beta (TGFb), platelet-derived growth 
factor (PDGF), insulin-like growth factor I and II (IGF I & II) and bone morphogenic 
protein (BMP). These factors initiate vascular invasion and migration of 
undifferentiated mesenchymal stem cells into the defect and stimulate proliferation and 
synthetic activity of the chondrocytes. Soon after migration the stem cells start to 
differentiate chondrogenically and synthesize extracellular matrix consisting of 
collagen type I and II and a relatively high amount of proteoglycans. 6 to 8 weeks after 
the injury the newly formed tissue fills the whole defect. But in terms of structure and 
composition the repair tissue is more similar to fibrocartilage than to hyaline cartilage. 
Only in the rarest cases the repair tissue is able to form a sufficient joint surface. Larger 
osteochondral injuries – if untreated - show signs of degeneration including 
fragmentation, fibrillation, loss of chondrocytes and increasing collagen type I and 
collagen type X content. The remaining material appears as a fibrous tissue and even 
this mostly decomposes leaving the underlying bone bare and unprotected [7]. 
 
As one can see there is a high demand for adequate medical treatment of articular 
cartilage damages.  
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1.4 Current therapy methods for articular lesions 
 
Currently different strategies are clinically used for treatment and repair of articular 
cartilage injuries: 
 
1.4.1 Bone marrow stimulation 
 
Based on the previously described repair mechanism of osteochondral defects 
methods have been developed to start that cascade of fibrin clot formation, stem cell 
migration and generation of fibrocartilage in articular lesions with conserved integrity 
of the subchondral bone. There are different variations among this technique such as 
subchondral drilling and microfracture. The microfracture as today’s most common 
technique was developed by Steadman. Across the whole defect the subchondral bone 
plate gets perforated with a special awl. The microfractures are set at a distance of 3-
4 mm to each other and down to a depth of 4 mm [17]. Unfortunately the fibrocartilage 
repair tissue ranks behind hyaline articular cartilage concerning biomechanical 
properties [7], [18] and paracrine function. But, particularly in young patients good 
clinical results with reduction of pain could be achieved [19]. This technique is 
adequate for treatment of small sized focal articular lesions. 
 
1.4.2 Mosaicplasty (Osteochondral grafts) 
 
This method was introduced in 1993 and since then frequently used for the therapy of 
chondral and osteochondral lesions [20]. Cylindric transplants composed of articular 
cartilage and subchondral bone are removed from healthy, low weight bearing articular 
areas and implanted into prepared holes in the defect zone. Good clinical results have 
been shown in several studies [20]–[22]. However, to receive the osteochondral grafts 
intact tissue has to be harmed which is a serious disadvantage of the therapy. Thus, 
the mosaicplasty is limited to small to medium sized focal defects. For larger defects 
allogeneic osteochondral allografts are available but limited in Germany due to 
regulatory specifications. 
 
 
 
	 10	
1.4.3 Autologous chondrocyte implantation 
 
Since its first description in 1987 the autologous chondrocyte implantation (ACI) [23]–
[25] has been continuously developed further and is used especially for the treatment 
of big chondral defects (>4 cm2). The initial step of the method is to take a small biopsy 
of healthy chondral tissue out of a non-affected and low-weight-bearing part of the joint. 
The chondrocytes are divided from the ECM by enzymatic digestion and proliferated 
in vitro. Depending on the dimension of the defect it takes 2 to 3 weeks of cell culture 
to get enough chondrocytes for a sufficient therapy [26]. In the course of the latest 
modifications the chondrocytes are imbedded in a three-dimensional matrix and then 
implanted into the chondral defect [25], [27]. Different biomaterials have been tested 
for the matrix-associated autologous chondrocyte transplantation (MACT) including 
collagen scaffolds, hyaluronan-based biodegradable polymer scaffolds [28] and 
polymers of poly-actin and poly-galactin [29]. The matrix containing the seeded cells 
can easily be adapted to the size and form of the lesion. After implantation the 
chondrocytes start to form a hyaline-like repair tissue, which leads to significant 
improvement for the patients in the form of improved function and reduced pain [23]–
[25]. Nonetheless there are considerable limitations for this technique. The leading 
problem is the restricted ability of differentiated chondrocytes to proliferate and therefor 
to generate an adequate number of cells. Additionally the risk of degenerative joint 
disease is increased by the removal of intact articular cartilage [25].  
 
There is a certain range of possible treatments for articular cartilage defects. However, 
any of these practicable options has serious disadvantages. So, there is still a need 
for a therapy that offers a functional cartilage replacement with the biomechanical 
properties of physiological articular cartilage and without the necessity to harvest cells 
or crafts by damaging healthy cartilage. This claim might be solved by the use of 
mesenchymal stem cells. 
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1.5 Mesenchymal stem cells in cartilage repair 
 
The introduction of mesenchymal stem cells (MSCs) with their ability to differentiate 
into cells of the chondrogenic lineage has started a new chapter in treatment of articular 
cartilage lesions. MSCs may have the potential to replace autologous chondrocytes in 
the therapy of cartilage defects and to provide even better results. Further on MSCs 
are available in huge numbers without the necessity of harming healthy cartilage 
tissue. 
 
1.5.1 Mesenchymal stem cells 
 
Mesenchymal stem cells (MSCs) are a promising source for the regeneration of 
mesenchymal tissue such as articular cartilage. They can be harvested with relatively 
low effort from different tissues like bone marrow [30] or adipose tissue [31]. MSCs are 
very proliferative and can easily be grown in vitro without losing the ability to 
differentiate chondrogenically. As MSCs are multipotent cells they are able to 
differentiate into a range of different mesenchymal tissues. Depending on extracellular 
conditions such as the composition of the medium and added growth factors they can 
form bone, cartilage, tendon, muscle, fat, dermis and other connective tissues [30], 
[32].	 The International Society for Cellular Therapy (ISCT) has proposed a set of 
standards to define MSCs. A cell can be classified as an MSC if it shows plastic 
adherent properties under normal culture conditions and has a fibroblast-like 
morphology. Cultured MSCs also express CD73, CD90 and CD105 on their surface, 
while lacking the expression of CD11b, CD14, CD19, CD34, CD45, CD79a and HLA-
DR surface markers [33].	
 
1.5.1.1 Chondrogenic differentiation of MSCs 
 
The high chondrogenic potential of MSCs has been proved in several different studies 
[34]–[37]. Furthermore there is a chance that they are able to recapitulate the 
embryonic lineage transitions originally involved in the formation of joint tissue [38]. 
Based on Johnstone’s in vitro chondrogenesis model for rabbit bone marrow derived 
MSCs [35] Yoo et al. developed a pellet culture system for human MSCs using a similar 
chondrogenic medium containing TGFb, dexamethasone, ascorbate, pyruvate, proline 
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and ITS. Under this influence MSCs differentiate chondrogenically, which is 
distinguished by gene expression and synthesis of the chondrogenic markers collagen 
type II, collagen type IX, collagen type XI and aggrecan [36]. In this model TGFb acts 
as the inducer of chondrogenesis. This is well established and confirmed by other 
authors [39], [40]. 
 
1.5.1.2 Hypertrophy in chondrogenesis of MSCs 
 
Unfortunately, chondrogenically differentiating MSCs tend to undergo hypertrophy in 
vitro such as transient growth plate chondrocytes in long bones. Despite more than 20 
years of research, this is one issue, that still makes them inappropriate for the clinical 
use in articular cartilage repair  [35], [36], [40], [41]. The hypertrophic phenotype is 
characterized by an increased cell volume including a swollen appearance of the 
chondrocytes. The ECM passes through a remodeling process that is accompanied by 
an increasing content of collagen type X, the degradation of collagen type II and 
aggrecan by matrix metalloproteinases (MMP) 3 and 13 and the activity of alkaline 
phosphatase (ALP), which induces the calcification of the ECM [35], [36], [40]–[42]. 
Furthermore, after chondrogenically pre-culture and ectopic in vivo transplantation in 
mice human MSCs showed induction of hypertrophy followed by vascular invasion and 
terminal matrix calcification. For comparison implanted human articular chondrocytes 
kept a stable chondrogenic phenotype without signs of hypertrophy [43]. This indicates 
that there are differences in the developmental program of cultured chondrogenically 
differentiating MSCs and articular chondrocytes that have to be overcome to produce 
appropriate repair tissue. While the behavior of MSCs under chondrogenic conditions 
is similar to that of growth plate chondrocytes, which also undergo hypertrophy and 
develop into transient enchondral cartilage, the differentiation of articular chondrocytes 
autonomously stops before the hypertrophic stadium to form stable articular cartilage. 
The developmental analogies between chondrogenically differentiating MSCs and 
growth plate chondrocytes were further described by Mueller and Tuan by 
demonstrating that chondrogenic differentiation of MSCs is equal to that shown by 
chondrocytes during endochondral embryonic skeletal development [42].  
In both cell groups genes acting as markers for chondrogenic differentiation and 
hypertrophy are regulated in a similar way. Additionally, their reaction to changes in 
medium composition is similar. Addition of thyroid hormone or bone morphogenic 
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protein-4 (BMP4) induces hypertrophy while TGFb and dexamethasone inhibit 
hypertrophy in MSCs as well as growth plate chondrocytes [39], [42], [44]. Karl et al. 
proved, that the pro-hypertrophic effect of thyroid hormone is mediated by BMP4. 
Based on that they established an in vitro hypertrophy model for MSCs, which we adopt 
for our study. In this model hypertrophy in chondrogenically differentiating MSCs can 
be increased by withdrawal of TGFb and dexamethasone and the addition of BMP4 
[44]. We use this model to make the impact of the anti-hypertrophic treatment more 
distinct. 
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1.6 Endochondral ossification 
 
Regarding the term of hypertrophy in chondrogenesis it is important to have a view at 
its physiological purpose in endochondral ossification. Endochondral ossification is the 
process behind the formation of vertebrate limb skeleton and length growth of long 
bones, which is characterized by the development of a chondral scaffold (growth 
cartilage) that is ultimately replaced by bone. Cartilage models (anlagen) are formed 
through condensation of mesenchymal cells that derive from three different sources: 
the neural ectoderm (cranial neural crest) for the craniofacial bones, the paraxial 
mesoderm for the axial skeleton and the lateral plate mesoderm for the skeleton of the 
limbs [45]. Mesenchymal cells in the center of the construct differentiate into highly 
proliferative pre-chondrocytes and express typical cartilage ECM molecules such as 
collagen II, IX, XI and aggrecan [46]. Cells in the outer zone of these ‘cartilage anlagen’ 
remain undifferentiated and form the perichondrium. Endochondral ossification in long 
bones takes place at two different ossification centers – the primary (diaphyseal) site 
and the secondary (epiphyseal) site in one or both end regions. Ossification starts in 
the diaphysis (primary site) with the formation of a bone collar that is built by 
perichondrium cells differentiating into osteoblasts. The epiphysis (secondary site) 
ossifies independently [46]. As an initial step a special subgroup of densely packed 
mesenchymal cells at the future joint site builds the avascular interzone which 
represents the first sign of joint formation. The interzone cells give rise to the 
permanent articular chondrocytes for both interlocking joint surfaces besides synovial 
lining, intra-articular ligaments and menisci. Meanwhile adjacent progenitor cells in the 
interrupted cartilaginous skeleton differentiate into chondrocytes that become 
organized in epiphysis and growth plate and undergo hypertrophy, vascular invasion 
and finally ossification [47]–[49].  
Each cell population is characterized by distinct expression patterns. Whereas 
interzone cells express growth and differentiation factor 5 (GDF5), a ligand for the BMP 
receptor 1β (BMPR1β) [14], chondrocytes in epiphysis, diaphysis and growth plate are 
GDF5- negative and express matrillin 1 instead, which is not present in any stage of 
articular chondrocyte development [15]. Chondrocytes in growth plate cartilage are 
arranged in specific zones depending on their functional and developmental state. The 
initially small and round chondrocytes build the resting zone, which is furthest from the 
ossification front, with a source of resting chondrocytes that supplies the adjacent zone 
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of proliferation (proliferation zone). The chondrocytes become flattened and packed 
into parallel, longitudinal columns. The cells reduce their proliferation activity and pass 
through the transient stage of the ‘pre-hypertrophic’ chondrocyte (pre-hypertrophic 
zone). Finally, they completely undergo hypertrophy in the hypertrophic zone, which is 
characterized by massive increase of cell volume and a switch in protein production 
towards collagen type X, MMP3 & 13 and ALP that initiates the calcification of the 
ECM. Subsequently hypertrophic chondrocytes die leaving the calcified cartilage 
matrix surrounding them largely intact. Blood vessels, osteoclasts and osteoprogenitor 
cells invade the chondral model and use the remaining cartilage matrix as a scaffold 
for bone formation [46], [50]–[52]. Recent studies were able to show that terminal 
differentiated chondrocytes in endochondral ossification are capable to survive, 
redifferentiate and contribute as osteoblasts to the then required bone formation [53]. 
During adolescence endochondral ossification still occurs in the growth plate, which is 
responsible for the longitudinal growth of the bones and clearly demonstrates the 
division of chondrocytes into different zones according to their maturation stage. 
Endochondral ossification is also necessary for secondary fracture healing as the 
callus, a cartilaginous template that is initially built in the fracture zone, is replaced by 
bone [54]. But apart from endochondral ossification there is another possible way of 
bone formation, the intramembranous ossification, which is responsible for the 
development of flat bones (e.g. the cranium). In contrast to endochondral ossification 
intramembranous ossification is not in need of a cartilage scaffold. After condensation 
the mesenchymal cells directly differentiate into osteoprogenitor cells. Maturated 
osteoblasts then produce and calcify the bone matrix [55].  
proliferation zone (round proliferating chondrocytes) 
proliferation zone (flat proliferating chondrocytes) 
pre-hypertrophic zone (pre-hypertrophic chondrocytes) 
hypertrophic zone (hypertrophic chondrocytes) 
resting zone (articular chondrocytes) 
FIGURE 3 Zonal structure of the growth plate during endochondral bone development. Mouse tibial 
growth plate. ALP staining (blue), neutral red as counterstaining (Source: www.histologyworld.com). 
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1.7 RAR-Pathway 
 
Retinoid signaling plays a key role in chondrocytes maturation and bone formation 
during limb skeletogenesis by regulating genes that influence cell growth, 
differentiation, survival and death.  
While retinoids induce hypertrophy and mineralization in the late stage of growth plate 
development [56], they are also capable of attenuating chondrogenesis in the early 
stage [57], [58]. Shimono et al. were able to inhibit heterotropic ossifications by orally 
administered retinoic acid receptor agonist treatment in mice. This effect was most 
likely traced back to the inhibition of the initial chondrogenic differentiation of MSCs as 
an inevitable early step of heterotropic ossification [59]. This correlates to the findings 
of Ballock et al. who showed that retinoic acid treatment of epiphyseal chondrocytes in 
monolayer culture results in a decreased expression of collagen II and aggrecan and 
an increased expression of the matrix metalloproteinases stromelysin-1 (MMP3) and 
collagenase 3 (MMP13) [60]. 
However, as endogenous retinoids are mainly distributed through the blood vessel 
system they are supposed to physiologically impact growth plate ossification mainly in 
the late stage, when blood vessels are sprouted into the growth plate cartilage [59], 
[61], [62]. In early skeletogenesis suppression of RAR signaling by unliganded RAR 
seems to be a crucial requirement for chondrogenesis and expression of pro-
chondrogenic genes and growth factors including Sox genes and BMPs [63]–[66]. 
There are two different subfamilies of intracellular retinoid receptors which are both 
located in the nucleus: the retinoic acid receptors, RAR α, β and γ, on one side and 
the retinoic X receptors, RXR α, β and γ on the other. There are two more RAR 
isoforms, RAR δ1 and δ2, however they cannot be found in human, but in amphibian 
stem cells [67], [68]. 
The RXRs respond to 9-cis-retinoic acid, a physiological isomer of all-trans-retinoic 
acid (tRA), and also act as heterodimeric partner for several nuclear receptors such as 
vitamin D, thyroid hormone and retinoic acid receptors [69].  
In the nucleus RAR and RXR form heterodimers and bind to specific retinoic acid 
response elements (RARE) located in the promoter area of several specific target 
genes. They operate as ligand-dependent transcription factors modulating target gene 
expression. In addition non-activated, non-liganded receptor complexes are involved 
in chromatin condensation, which inhibits gene transcription [70].  
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RARγ seems to be the most important retinoid receptor for limb development. Mutant 
mice that are deficient in RARα or RARβ expression show normal phenotypes whereas 
the growth plates of RARγ deficient mice are defective and lack in aggrecan expression 
and content [71]. According to this finding RARs show distinct differences in gene 
expression during enchondral ossification. Both, different timing and distinct spatial 
distribution is found. Whereas RARα expression remains broad and diffuse and RARβ 
is restricted to the perichondrium, RARγ is highly expressed in hypertrophic cells and 
expression is selectively up-regulated just before the chondrocytes undergo 
hypertrophy [58]. 
The RARs interact with different co-regulators. Depending on the binding ligand bonds 
to co-activators (CoA) or co-repressors (CoR) are reinforced or weakened [72]. Further 
on CoAs are necessary for correct binding of agonists and downstream signaling. 
RAR-CoR constructs however handicap the binding of agonists and therefore 
decrease or even inhibit downstream RAR signaling. 
In avascular cartilage zones RARs exert ligand-less receptor function. Non-liganded 
RARs built complexes with CoR, which represses target gene transcription by probably 
promoting chromatin condensation. Under retinoid free conditions RARs, especially 
RARγ, are beneficial for proteoglycan expression in chondrocytes [70], [73]. 
While inactive vitamin A is stored in the liver, released retinol is bound to plasma 
retinoid binding proteins (RBPs) forming a hydrophobic complex on their way to target 
cells. In many tissues retinol is transported through the cell membrane by the specific 
RBP receptor STRAT6 (“stimulated by retinoic acid” RBP receptor/Vit. A transporter) 
and intracellular transferred into active all-trans retinoic acid by retinol dehydrogenases 
(RDHs) and retinaldehyde dehydrogenases (RALDH) [66], [74]–[76]. 
Intracellular retinoids in cytoplasm are associated to special binding proteins that are 
involved in cell uptake of retinoids, protect them from non-specific interactions, control 
intracellular retinoid distribution and transport them between cellular compartments. 
The cellular retinoic acid binding protein II (CRABPII) transfers retinoic acid to the 
nucleus and delivers it to RAR by “channeling” via direct protein-protein contact without 
dissociation of the ligand into the aqueous phase. Thus CRABPII promotes formation 
of the RAR-RA complex and stimulates the RA-induced transcriptional activity of RAR 
[77]–[79]. 
The binding of the physiological agonist tRA to RAR effects the release of CoR and 
the binding of CoA, which leads to chromatin modification and subsequent activation 
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of gene expression for example of the transcriptional factor MafB and proteins involved 
in the Wnt/β-Catenin pathway. This is followed by expression of the matrix 
metalloproteinases MMP3 and MMP13 as a sign of hypertrophy in chondrocytes [72], 
[80]. Jimenez et al. furthermore demonstrated that the RA induced expression of 
MMP13 is mediated by runt-related transcription factor 2 (Runx2) as targeted deletion 
of the Runx2 gene in mice nearly completely inhibited MMP13 gene expression [81]. 
In our model we analyze the impact of the treatment with a special type of retinoid 
antagonist, BMS204,493 (further named BMS), which works as a pan-RAR-inverse 
agonist (binds to all three RARs). As an inverse agonist (IA) BMS has to be 
distinguished from neutral antagonists that are only capable of competitive 
replacement of agonists. BMS causes a more active process and increases CoR 
interactions compared to the unliganded receptor state [72], [82], [83]. 
    
 
 
 
 
 
 
 
 
 
 
FIGURE 4 Structures of the RAR agonist all-trans retinoic acid and the pan-RAR inverse 
agonist BMS493  
all-trans Retinoic Acid (RA) BMS204,493 (BMS493) 
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1.8 Wnt/β-Catenin signaling 
 
In chondrocytes one important pathway to interact with the RAR pathway is the Wnt/β-
Catenin signaling pathway. Through activation of this pathway gene expression of 
aggrecan and collagen II is inhibited, and expression of metalloproteinases is 
activated, which leads to matrix degradation in cartilage. 
Retinoid signaling stimulates Wnt/β-Catenin signaling as Wnt, particular Wnt 2b and 
5a, and Wnt receptors and co-receptors (Frizzeleds and lipoprotein receptor related 
protein (LRP) 5/6) are target genes of the RAR pathway. 
When Wnt proteins bind to cell surface complexes of these receptors and co-receptors, 
phosphorylation of β-Catenin by glycogen synthase kinase 3 (GSK3) decreases. Non-
phosphorylated β-Catenin doesn’t undergo degeneration through the proteasome 
pathway and accumulates in the cytoplasm. 
After translocation to the nucleus it interacts with lymphoid enhancer factor/T cell factor 
(Lef/Tcf) transcription factors and activates expression of direct and indirect target 
genes. Runx2 [84] and subsequently MMPs and collagen type X expression is up-
regulated [85], whilst SOX9 (SRY related HMG box 9) [86] and therefore aggrecan and 
collagen type II expression is decreased [87]. 
Yasuhara and co-workers showed that both retinoic acid (RA) and Wnt3a treatment 
inhibits gene expression of Aggrecan and up-regulates expression of MMP13 and 
MMP3 in chondrocytes by stimulating Wnt/ β-Catenin signaling. Co-treatment with RA 
and Wnt3a enhance these effects [88]. However, RA treatment decreases Wnt/ β-
Catenin signaling in other mesenchymal cells. Thus, responses to retinoid and Wnt/ β-
Catenin signaling are supposed to change during chondrogenic cell differentiation as 
a sign of distinct temporal signaling mechanisms.  
Some results indicate that under retinoid free conditions RARs inhibit Wnt/ β-Catenin 
signaling in chondrocytes and thus act as pro-chondrogenic receptors [88]. Figures 5 
and 6shows possible cross-regulations between the two pathways. 
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 FIGURE 6 Schematic demonstration of the 
inhibition of the RAR pathway by BMS493 
BMS493 is translocated into the nucleus by 
CRABP II and binds to the RAR/RXR complex. 
Binding of the inverse agonist leads to a 
destabilization of co-activator bounds and 
supports co-repressor recruitment. The 
receptor complex subsequently inhibits target 
gene expression at the promoter area RARE. 
The reduced expression of Wnts and Wnt 
receptors and co-receptors decreases 
hypertrophic differentiation. CoA co-activator 
CoR co-repressor CRABP II cellular retinoic 
acid binding protein GSK3 glycogen synthase 
kinase 3 LEF/TCF lymphoid enhancer binding 
factor/T cell factor LRP lipoprotein receptor 
related protein RAR retinoic acid receptor 
RARE retinoic acid response element RXR 
retinoic X receptor  
 
OH 
COOH Retinoic acid 
FIGURE 5 Possible connections of Wnt/ß-catenin and retinoid signaling pathways. 
The retinoic acid is translocated into the nucleus by CRABP II. Binding of retinoic acid (RA) to the RA 
receptor would activate gene expression of Wnt proteins, receptors, and co-receptors which leads to an 
increased Wnt/ß-Catenin signaling followed by hypertrophic conversion.  
CoA co-activator CRABP II cellular retinoic acid binding protein GSK3 glycogen synthase kinase 3 
LEF/TCF lymphoid enhancer factor/T cell factor LRP lipoprotein receptor related protein MMP13 matrix 
metalloproteinase 13 RALDH Retinaldehyde dehydrogenase RAR retinoic acid receptor RARE retinoic 
acid response element RBP retinoid binding protein RDH retinol dehydrogenase RunX2 runt-related 
transcription factor 2 RXR retinoic X receptor SOX9 SRY related HMG box 9 STRAT6 “stimulated by 
retinoic acid” RBP receptor/Vit. A transporter  
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1.9 TGFβ superfamily 
 
The transforming growth factor β superfamily is a big group of signaling molecules 
encoded by 33 genes. Its name is derived from the first member of the family to by 
isolated. Apart from TGFβ the group includes bone morphogenetic proteins (BMPs), 
growth and differentiation factors (GDFs), activins and inhibins. Members of the family, 
which are expressed in both vertebrates and invertebrates, can be found in nearly any 
tissue and operate from the very first steps of development throughout lifetime of living 
beings. They play elementary roles in the regulation of various biological processes 
such as cell growth and differentiation, pattern formation and regulation of the immune 
system [89], [90]. 
 
1.9.1 TGFβ signaling 
 
An important requirement for the initiation of chondrogenesis and the prosecution of 
chondrogenic differentiation is the activity of TGFβ signaling and further downstream 
pathways. The pro-chondrogenic effect of TGFβ in vitro and in vivo has been 
demonstrated in several studies. TGFβ signaling promotes chondrogenic 
differentiation yet inhibits chondrocyte hypertrophy and terminal differentiation [91]–
[97]. Accordingly TGFβ expression is activated in the early stage of chondrogenesis 
but not in hypertrophic chondrocytes [98], [99]. 
There are two subtypes of TGFβ receptors, TGFβR1 and TGFβR2, which form a 
heterodimeric serine/threonine kinase receptor complex. The signaling starts with the 
binding of ligands to the receptor complex. TGFβR2 phosphorylates TGFβR1, which 
again phosphorylates and activates the associated Sma and Mad related proteins 
(SMADs), SMAD2 and SMAD3. After phosphorylation and translocation to the nucleus 
SMAD2/3 cooperate in a complex with SMAD4 acting as a transcriptional factor, that 
up-regulates the expression of the target gene SOX9. SOX9 is essential for the 
initiation of chondrogenesis and furthermore for the maintenance of chondrogenic 
differentiation. Simultaneously TGFβ signaling in general is down-regulated during 
hypertrophic conversion in chondrocytes [100], [101].  
SOX9 forms a complex with SMAD2, SMAD3 and SMAD4 that promotes target gene 
expression. During chondrogenic differentiation SOX5 and SOX6 are co-expressed 
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with SOX9 and necessary as co-factors for an adequate expression of collagen type 
II, aggrecan and other cartilage specific genes [102]–[105]. 
The TGFβ pathway is modulated on different levels. SMAD6 and SMAD7 have an 
inhibiting effect on the activity of SMAD2/3 and consequently reduce TGFβ signaling. 
The membrane anchored molecules betaglycan and endoglin both exert influence on 
the TGFβ pathway by binding TGFβ subtypes but with converse outcome. While 
betaglycan enhances TGFβ signaling endoglin seems to reduce TGFβ signaling [106]. 
Additionally TGFβ signaling is dependent on the activation of latent TGFβ as all three 
subtypes, TGFβ1, TGFβ2 and TGFβ3, are synthesized in an inactive form [107]. 
 
1.9.2 BMP signaling 
 
Further members of the TGFβ superfamily that fulfill a crucial function in limb 
development are bone morphogenic proteins (BMPs). The subfamily of BMP related 
proteins contains over 20 multi-functional cytokines, however especially BMP2, 4, 6 
and 7 are known to affect endochondral ossification [108]–[111]. The exact role of 
BMPs is far from defined but various studies suggest them to be an important part of 
the regulation mechanism of cartilage formation and development. BMP signaling is 
supposed to promote aggregation of mesenchymal cells into pre-chondrogenic 
condensations [112] and to stimulate chondrogenic differentiation and expression of 
chondrogenic markers such as collagen type II and aggrecan [113]–[116]. Although 
BMPs might have a protective effect in articular cartilage, they also seem to be involved 
in chondrocyte hypertrophy and matrix degradation. Several in vitro and in vivo studies 
showed that BMPs effected an increased hypertrophic conversion in chondrocytes 
including increased expression of hypertrophic markers like collagen type X and ALP 
and that inhibition of BMP signaling prevents chondrocytes hypertrophy [109]–[111], 
[116]–[120]. According to this Karl and Mueller developed a BMP4 based hypertrophy 
model for pellet culture of MSCs [44], which we use in our study as well.  
 
BMP signaling is mediated by a dimeric transmembrane receptor complex built of type 
I and type II serine/threonine kinase receptors. Analogously to TGFβ signaling ligand 
binding starts a cascade of phosphorylation within the receptor complex, which 
concludes with the activation of intracellular signaling molecules (SMAD1, 5 and 8). 
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Activated SMAD1/5/8, form a complex with SMAD4 to regulate target gene expression 
in the nucleus [121], [122].  
The ways of regulating the BMP pathway are diverse. Similarly, to TGFβ signaling the 
inhibitory SMAD6 and 7 decrease phosphorylation of SMAD1/5/8. Extracellular BMP-
specific antagonists such as noggin, chordin, follistatin and gremlin can influence the 
level of ligand availability by complexing with BMPs and preventing them from 
interacting with their receptor [123]–[125]. Furthermore, the pseudoreceptor BAMBI 
(BMP and activins membrane-bound inhibitor) disturbs the interactions between type I 
und type II receptor of the TGFβ superfamily as it is a transmembrane protein structural 
similar to the type I receptor but without enzymatic activity. During embryonic 
development BAMBI is co-expressed with BMP4 and therefore functions as a negative 
feedback regulator for BMP signaling [126]. 
 
BMP signaling leads to an up-regulation of Runx2 expression [127], [128]. Runx2, also 
called core binding factor subunit α1 (CBFA1), belongs to the runt-domain gene family, 
whose members are characterized by the DNA-binding domain runt [129]. It acts as a 
stimulator of hypertrophy in differentiating chondrocytes as various hypertrophic 
markers including collagen type X [130] and MMP13 [131] were identified as Runx2 
targets. Furthermore Runx2 cooperates with the BMP associated transcription factors 
SMAD1/5/8 to induce collagen type X gene expression [130]. Runx2 expression 
increases corresponding to chondrocyte differentiation. The gene expression level of 
Runx2 is low in resting and proliferating chondrocytes and highest in terminal 
maturated hypertrophic chondrocytes [132]–[134].  
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2 Aim of the study 
 
Mesenchymal stem cells (MSCs) seem to be the right candidate cells for the treatment 
of articular cartilage lesions. They can easily be obtained in appropriate quantity and 
have the potential to differentiate chondrogenically. But regrettably, current models for 
in vitro chondrogenesis of MSCs induce a hypertrophic differentiation that is similar to 
the developmental program of growth plate chondrocytes during enchondral 
ossification rather than to pheno- and genotypically stable articular chondrocytes. So, 
as we are looking for a stable and functional replacement tissue for cartilage defects 
and hypertrophy would result in apoptosis and ossification the concern for tissue 
engineering applications for cartilage repair using MSCs rises. Before MSCs can be 
used adequately in cartilage repair, the in vitro chondrogenesis protocols have to be 
improved to a point, where hypertrophy can be attenuated completely and permanent 
chondrogenic differentiation can be reliably induced.  
In order to find a way to inhibit hypertrophy in this study we concentrate on the RAR-
pathway. Retinoid signaling plays a key role in chondrocytes maturation during limb 
skeletogenesis. As retinoids induce hypertrophy and mineralization and attenuate 
chondrogenic differentiation it could have a positive effect on chondrogenesis of MSCs 
to inhibit RAR signaling. To achieve a RAR inhibition we use a special antagonist called 
BMS493, which acts as a pan-RAR inverse agonist. In our study we analyze if BMS 
treatment has an impact on hypertrophy of chondrogenically differentiated human 
MSCs (hMSCs) in vitro. And since the effect of retinoic acid to growth plate 
chondrogenesis depends on the state of differentiation we investigate if BMS 
application at different time points leads to different outcomes. 
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3 Materials and methods  
 
3.1 Materials 
 
3.1.1 Recombinant Proteins 
 
Chemical Application Concentration Company 
BMP4 BMP ligand 25 ng/ml R&D systems 
TGFb1 TGFb ligand  10 ng/ml R&D systems 
BMS204,493 Pan-RAR inverse 
agonist 
2 μM Sigma 
TABLE 1 Recombinant Proteins 
 
 
3.1.2 Primers 
 
Primers were synthesized by eurofins. Solutions of 100 μM (100 pmol/μl) were 
prepared and stored at -80°C. The following primers were used. 
 
Gene Sequence (forward) Sequence (reverse) Concentration 
VPS29 AGCTGGCAAACTGTTGCAC GACGGTGGTGGTGACTGAG 200 nM 
PSMB4 GCTTAGCACTGGCTGCTTCT GGACATGCTTGGTGTAGCCT 200 nM 
REEP5 AGGTCAGCCACTGGGTATCA CCTCTCTCCTCTGCAACCTG 200 nM 
MMP13 GACTGGTAATGGCATCAAGGGA CACCGGCAAAAGCCACTTTA 200 nM 
COL1A1 ACGTCCTGGTGAAGTTGGTC ACCAGGGAAGCCTCTCTCTC 200 nM 
COL2A1 GGGCAATAGCAGGTTCACGTA TGTTTCGTGCAGCCATCCT 200 nM 
COL10A1 CCCTCTTGTTAGTGCCAACC AGATTCCCAGTCCTTGGGTCA 200 nM 
TABLE 2 List of primers. Genes are abbreviated according to the NCBI gene database 
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3.1.3 Antibodies 
 
Primary antibodies 
Antibody Dilution Company 
Collagen type II (mouse) 1:100 Calbiochem 
Collagen type X (mouse) 1:20 Quartett 
Immunodiagnostica 
Secondary antibodies   
Goat-ant-rabbit (HRP-conjugated) 1:1000 Pierce 
Goat-anti-mouse (biotinylated) 1:100 Dianova 
TABLE 3 List of antibodies   
 
 
3.1.4 Kits 
 
Name Application Company 
Alkaline Phosphatase Kit  ALP staining Sigma Aldrich 
Brilliant SYBR Green 
QPCR Master Mix 
qPCR Agilent Technologies 
DC Protein Assay Protein concentration Biorad 
Quant-it Pico Green 
dsDNA-Kit 
DNA concentration Invitrogen 
RNeasy Plus Universal Kit RNA clean up, DNA 
digestion 
Qiagen 
Transcriptor First Strand 
cDNA Synthesis 
cDNA synthesis Roche 
Vectastain Elite ABC HRP 
Kit 
Immunohistochemical 
Collagen staining 
Vector Laboratories  
Pierce DAB Substrate Kit  Immunohistochemical 
Collagen staining 
Thermo Fisher Scientific 
TABLE 4 List of kits 
 
 
3.1.5 Buffers and solutions 
 
Tris 0,2 M (pH 7,0) 
24,2 g Tris base 
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add H2O to 1l 
Washing Buffer  
780 ml Tris 0,2 M (pH 7,0) 
2,4 g NaCl 
60 ml Triton X100 
1% FCS 
1% goat serum 
add H2O to 250 ml 
 
Blocking Buffer  
120 ml Tris 0,2 M (ph 7,0)  
2,4 g NaCl  
60 ml Triton X100  
1% FCS  
1% goat serum  
add H2O to 250 ml 
 
McIlvain Buffer (pH 3,6) 
6,8 mM Citric acid  
6,4 mM Na2HPO4  
 
PBS 
137 mM NyCl 
2,7 mM KCl 
10 mM Na2HPO4 x 2 H2O 
2 mM KH2PO 
 
Phosphate-Buffer (0.2 M) 
29,7 g Na2HPO4 
4,6 g NaH2PO4 
add H2O to 1l 
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ALP Buffer  
1,5 M Tris (pH 9,0) 
1 mM Mg Cl 
1mM ZnCl 
 
3.1.6 Cells  
 
Human mesenchymal stem cells (MSCs) derived from the iliac crest of male patients 
aged under 60 (n=3) were used for the experiments. Cell harvest was approved by the 
ethical committee of Regensburg University Medical Center end performed after 
written information and consent of the patient. Cells were made anonymous after 
harvest for further investigation. 
 
3.1.7 Cell culture media 
 
Proliferation medium: 
Dulbecco’s modified Eagle’s medium (DMEM) low glucose (Invitrogen) with 10% fetal 
calf serum (PAN Biotech GmbH) and 1% penicillin/streptomycin (Invitrogen). 
Differentiation medium: 
Chondrogenic medium: DMEM high glucose  (Invitrogen), 1% ITS+3 (Sigma Aldrich), 
100 nM dexamethasone (Sigma Adrich), 40 μg/ml L-proline (Sigma Aldrich), 50 μg/ml 
ascorbate-2-phosphat (Sigma Aldrich), 10 ng/ml TGFb1 (R&D Systems). 
Hypertrophic medium: DMEM high glucose, 1 % ITS+3, 50 μg/ml ascorbate-2-
phosphate, 40 μg/ml L-proline, 25 ng/ml BMP4 (R&D Systems) 
 
Test group medium additionally contained 2 μM BMS204,493 (Sigma Aldrich).  
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3.2 Methods 
 
3.2.1 Cell culture 
 
3.2.1.1 Isolation of MSCs 
 
Human MSCs were isolated from bone marrow aspirates of male patients’ iliac crest 
undergoing surgery that required autologous bone grafting with approval of the ethics 
committee of the University of Regensburg and written consent. MSCs were isolated 
by Ficoll gradient centrifugation. Therefore, bone marrow medium mixture was 
carefully layered onto a Ficoll (Biochrom) cushion in a 50 ml Falcon tube. The Falcon 
tube was then centrifuged for 35 minutes at 1680 U/min. The cell pellet, in which MSCs 
are located, was collected from the 1,077 g/ml density interface and mixed with fresh 
proliferation medium. After a further centrifugation step (10 min, 1000 U/min), the pellet 
was resuspended in fresh medium, the cell number was determined, and the cells were 
plated at a density of 2 million cells per 75 cm2 
 
3.2.1.2 Expansion of MSCs  
 
MSCs were cultured as monolayer in 15 ml proliferation medium in 75 cm2 tissue 
culture flasks. Cells were maintained at 37 °C in a humidified atmosphere containing 
5 % CO2. Medium changes were performed every three to four days and at 80 % 
confluence cells were trypsinized and frozen for later use in liquid nitrogen. 
 
3.2.1.3 Differentiation of MSCs 
 
The chondrogenic differentiation of the MSCs was initiated according to the in vitro 
chondrogenesis model established by Johnstone et al  [35]. MSCs of passage two 
were used for the experiments.  
After unfreezing MSCs were seeded in 75 cm2 tissue flasks at a number of 
approximately 500.000 cells per flask and expanded in proliferation medium until 80% 
confluence was reached. Cells were washed with sterile PBS and 3 ml trypsin (PAN 
Biotech GmbH) was added to remove the cells from the surface under gently shaking. 
The trypsin was inactivated with fresh proliferation medium and the cell suspension 
was then centrifuged for 5 minutes at 1000 U/min. The cell clot was resuspended in 
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DMEM high glucose medium and cell concentration was determined. Cells were 
seeded in V-bottomed 96-well polypropylene plates at a number of 200.000 per well 
and pellets were formed by centrifugation at 250 g for 5 minutes. Cells were 
chondrogenically differentiated in chondrogenic medium (as indicated in 3.1.7) for 14 
days. During this phase one group of aggregates additionally was treated with BMS (2 
μM). After these 14 days of chondrogenic pre-differentiation, pellets were split into 
seven groups and cultivated for another 14 day under different medium conditions (as 
described in 3.2.1.4). 
MSC aggregates were kept at 37 °C in a humidified atmosphere containing 5 % CO2. 
Medium was changed three times per week. MSC pellets were isolated at different 
time points and specified histologically, histochemically and immunohistochemically. 
Furthermore, ALP activity, GAG content, gene expression and protein expression were 
analyzed.  
 
(Shum, 2002)  
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FIGURE 7 Sequence of the cell culture Human mesenchymal stem cells are isolated from bone 
marrow aspirates of the iliac crest of different donors. The cells are expanded in monolayer culture and 
transferred into 96-well plates at passage 2. Pellets are formed by centrifugation and incubated in 
differentiation medium for 4 weeks. Chondrogenesis can be induced with a well established 
chondrogenic medium containing TGFβ and dexamethasone. Furthermore, hypertrophy can be 
stimulated by withdrawal of TGFβ and dexamethasone and addition of BMP4.  
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Differentiation 
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3.2.1.4 Modulation of hypertrophy 
 
MSC pellets were formed as described and differentiated in chondrogenic medium for 
14 days treating one part of cells additionally with BMS (as indicated in 3.2.1.3). On 
day 14 aggregates were divided into seven different groups with different proliferation 
media forming pairs of one respectively two test groups and one associated control 
group, which differ in the addition of BMS to the test groups’ medium: 
(1) control group: chondrogenic medium; (2) test group: chondrogenic medium with 2 
μM BMS493; 
(3) control group: chondrogenic medium without TGFb1; (4) test group: chondrogenic 
medium without TGFb1 but with 2 μM BMS493; 
Note: The established chondrogenic medium contains TGFb1 because of its 
chondrogenic potential. Through this test constellation we want to investigate, if 
BMS, which is also supposed to have a chondrogenic effect, is able to 
compensate the lack of TGFb1 and generate a chondrogenic phenotype. 
(5) control group: hypertrophic medium (as indicated in 3.1.7); (6) test group A: 
hypertrophic medium with 2 μM BMS493; (7) test group B: addition of 2 μM BMS493  
to the chondrogenic medium only during predifferentiation and switching to 
hypertrophic medium on day 14; 
Note: Through these two hypertrophic test groups the effect of BMS treatment during 
different phases of chondrogenesis can be investigated. 
Cells for gene expression analysis were isolated on day 0, day 1, day 14 and day 28. 
For GAG assay aggregates were harvested on day 1, day 14, and day 28. Aggregates 
for histological analysis and medium supernatant for ALP activity analysis were 
isolated on day 14 and day 28. 
Figure 8 shows the line-up of the different test and control groups and their different 
medium conditions. 
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3.2.2 Histology, Histochemistry and Immunohistochemistry  
 
3.2.2.1 Fixation of MSC pellets and preparation of frozen sections  
 
MSC aggregates were isolated on day 14 and day 28 and fixed in 4% 
paraformaldehyde for one hour. Then the pellets were rinsed with 0,1 M phosphate 
buffer and incubated for an hour each in sucrose solutions of increasing concentration 
(10%, 20%, 30% sucrose solution in 0,1 M phosphate buffer). Afterwards MSC 
aggregates were embedded in TissueTec (Sakura) and frozen in liquid nitrogen. 10 
μm thick cryo sections were prepared with the Microm HM 500 OM Cryotom (Microm, 
Berlin, Deutschland). 
 
 
FIGURE 8 Classification of Aggregates into different test and associated control groups with 
different composition of proliferation medium. Late and early BMS group additionally marked. 
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3.2.2.2 DMMB staining 
 
1,9-Dimethylmethylenblue (DMMB) stains sulfated glucosaminoglycans (GAGs) that 
form a main part of the cartilage extracellular matrix and are synthesized by 
chondrocytes during chondrogenesis. Frozen sections were rehydrated in distillated 
water for 5 minutes and incubated in 0,1% DMMB solution (Sigma Aldrich) for 10 
minutes. Afterwards sections were washed twice with distillated water and dehydrated 
with alcohol of increasing concentration (1x 90% propanol, 2x 96% propanol, 2x 100% 
propanol, 5 minutes each) and Xylol (2x 100% Xylol, 5 minutes each) as final step. 
Cover slips were attached with DePex solution (Serva Electrophoresis GmbH). 
Sections were analyzed under the microscope at 4x and 10x magnification. 
 
3.2.2.3 Alkaline phosphatase (ALP) staining 
 
For ALP staining an alkaline phosphatase kit was used according to manufacturer’s 
instructions. Neutral red (3-Amino-7-dimethylamino-2-methylphenazinhydrochlorid) 
was used as counterstaining. Cover slips were attached with 70% sorbitum solution 
(Caelo). Sections were analyzed under the microscope. 
 
3.2.2.4 Immunohistochemistry 
 
Immunohistochemistry was used for collagen type II and X staining. Therefore, 
Sections were rehydrated in washing buffer for approximately 10 minutes. Then 
endogen peptidases were inhibited with 3% H2O2/ 10% Methanol in PBS for 30 
minutes. Sections were rinsed three times with washing buffer. Before blocking pepsin 
digestion for antigen preparation was carried out for 15 minutes at room temperature. 
For collagen type X staining an additional hyaluronidase digestion for one hour was 
performed before pepsin digestion. Then sections were incubated in blocking buffer 
for one hour at room temperature, followed by incubation in a solution of the particular 
primary antibody in blocking buffer overnight at room temperature. Immunolabeling 
was detected with a biotinylated secondary antibody, horse reddish peroxidase (HRP) 
conjugated avadin (Vector Laboratories) and enhanced diaminobenzidine (DAB) as 
substrate (Sigma). 
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3.2.3 Microscopy 
 
To investigate the stained sections following microscope was used: Nikon ECLIPSE 
TE 2000-U 
 
3.2.4 Gene expression analysis 
 
3.2.4.1 RNA isolation and cDNA synthesis 
 
For gene expression analysis aggregates of every culture condition were isolated on 
day 28. Additionally, aggregates of group 1 and group 7 were harvested on day 1 and 
day 14. Furthermore, the cells of two tissue flasks on day 0 had been isolated, before 
pellets were formed. 8 to 10 pellets per condition and per time point as well as the cells 
of day 0 were pooled, incubated in 0,9 ml Qiazol (Qiagen) and homogenized using the 
Precellys24 homogenizer (bertin instruments). The aqueous phase was transferred 
into a fresh tube and RNA was isolated using the RNeasy Plus Universal Kit (Qiagen). 
In brief, initially 100 μl gDNA-Eliminator solution and then 180 μl chloroform were 
added and the tube was shaken for 15 seconds after each step. Then the solution was 
incubated at room temperature for 15 minutes and centrifuged for 15 minutes at 12000 
g and 4°C. Supernatant (approximately 0,6 ml) was again isolated and mixed with at 
least an equal amount of 70% Ethanol. The solution was then filtrated in special tubes 
by centrifugation at 8000 g and eluted in 30 μl RNase free water. RNA concentration 
was measured using the 2100 Bioanalyzer (Agilent Technologies).  
1 μg RNA was reverse transcribed in cDNA using the Transcriptor First Strand cDNA 
Sythesis kit (Roche) according to manufacturer’s instructions. 
 
3.2.4.2 Real time polymerase chain reaction (PCR) 
 
Gene expression was analyzed by semiquantitative real time PCR. Therefore, a real 
time PCR Detection System (CFX96, Biorad) was used in combination with Brilliant 
SYBR Green QPCR Master Mix (Agilent Technologies). The optimal primer 
concentration for each gene was identified through previous tests and is listed in table 
2. cDNA was diluted to a concentration of 1 ng/μl. For PCR a final volume of 20 μl was 
used containing 10 μl Brilliant SYBR Green QPCR mix, 0,2 μl forward primer, 0,2 μl 
reverse primer, 4,6 μl RNase free water and 5 μl of the cDNA sample. PCR was 
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performed under following conditions. Initially DNA was denatured at 95°C for 15 
minutes followed by 40 cycles of alternating denaturation (10 second, 95°C) and primer 
annealing and extension (30 seconds, 60°C). Melting temperature of the PCR product 
was analyzed by continuous measurement of fluorescent intensity during slow heating 
from 55°C to 95°C. Gene expression was normalized to following reference genes: 
Vacuolar Protein Sorting 29 (VPS29), Proteasome Subunit Beta Type 4 (PSMB4) and 
Receptor Expression Enhancing Protein 5 (REEP5). 
 
3.2.5 Biochemical analysis 
 
3.2.5.1 GAG analysis 
 
Sulfated glycosaminoglycan (GAG) content relativized to DNA content was used as a 
quantitative marker for chondrogenic differentiation. For GAG analysis 4 to 5 
aggregates were harvested on day 1, day 14 and day 28 and digested in 200 μl papain 
digestion solution (150 μg/ml Papain (Sigma) in PBS, 6 mM L-Cystein (Merck), 6mM 
EDTA (Sigma), pH 6.0) at 60°C over night. GAG content was determined with the 
DMMB method and chondroitin sulfate A from bovine trachea (Sigma Aldrich) was 
used as a standard. DNA content was measured with the Quant-it Pico Green dsDNA-
Kit (Invitrogen) according to manufacturer’s instructions. 
 
3.2.5.2 Alkaline phosphatase activity 
 
ALP activity was determined densitometrically by measuring the change in the 
absorbance at 405 nm through the transformation of p-nitrophenyl phosphate to p-
nitrophenol and inorganic phosphate [108]. Therefore, medium supernatant was 
isolated on day 14 and day 28 and centrifuged for 5 minutes at maximum speed. 75 μl 
of supernatant was transferred to a 96-well flat bottom plate and 75 μl substrate 
solution (4mg/ml p-nitrophenol phosphate (Sigma Aldrich) in ALP buffer) was added. 
Continuous absorbance at 405 nm was measures spectrophotometrically in a Genius 
plate reader (Tecan) at room temperature. The change in A405 over time (dA/min) was 
calculated in the linear range of the reaction. 
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3.2.6 Statistical analysis 
 
The data from real time PCR analysis, ALP activation analysis and GAG content 
analysis were expressed as mean values ± standard deviation (SD). Each experiment 
was performed with cells of marrow preparations of three different donors. The one-
way Anova Test in SPSS statistic software (IBM) in combination with the Tukey Post-
Hoc-Test was used for statistical analysis. A level of p<0.05 was considered significant. 
 
All methods had been previously described in parts [44]. 
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4 Results 
 
4.1 Differentiation of MSC aggregates under chondrogenic and 
hypertrophic conditions 
 
To start with the basis for our actual experiments we investigated MSC aggregates 
that had been treated with chondrogenic differentiation medium on different time points 
histologically, biochemically and on gene expression level and compared them to MSC 
aggregates under hypertrophic medium conditions. 
 
4.1.1 Over time development of MSC aggregates under chondrogenic 
conditions 
 
Besides the pellets obtained at the end of cell culture on day 28 we also isolated MSC 
aggregates on day 14 and cells on day 1 to track the course of the differentiation under 
established chondrogenic medium conditions. Therefore, histological analyses and 
real time PCR were carried out.  
Histologically the aggregates showed a distinct progression of chondrogenesis over a 
period of two weeks. While the cell density of pellets on day 14 (FIGURE 9 A, B, C, D) 
is high because of a low content of ECM the volume of the aggregates has been 
multiplied on day 28 (FIGURE 9 E, F, G, H) and there was a large area of ECM around 
each cell. The content of GAGs was equal at both time points (FIGURE 9 B, F) however 
collagen type II staining was much stronger and more homogenous on day 28 
(FIGURE 9 G) compared to aggregates on day 14 (FIGURE 9 C), which indicates the 
production of a cartilaginous ECM. However, MSC pellets on day 28 also show first 
signs of hypertrophic conversion. ALP staining was detected in the outer zone of the 
aggregates (FIGURE 9 E) and immunohistochemical analysis results in an appreciable 
presence of collagen type X in the whole pellet on day 28 (FIGURE 9 H), whereas 
pellets on day 14 were free of these hypertrophic markers (FIGURE 9 A, D). 
The histological results were confirmed by gene expression analysis of pellets on day 
1, 14 and 28. The collagen type II gene expression was statistically significantly 
upregulated from day 14 to day 28 whereas collagen type I gene expression was on a 
constant level during the whole cell culture. Analogous to immunohistochemical 
staining expression of the hypertrophic marker collagen type X was statistically 
significantly increased from day 14 to day 28 however there were no statistically 
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significant differences in the gene expression of the second hypertrophic marker 
MMP13 between any time points. 
 
 	
			
FIGURE 9 Histological Appearance of MSC aggregates on day 14 (A, B, C, D) and day 28 (E, F, 
G, H) of pellet culture under chondrogenic conditions. A, E alkaline phosphatase (ALP) staining 
(blue) with neutral red as counterstaining. B, F DMMB staining. C, G immunohistochemical collagen 
type II staining. D, H immunohistochemical collagen type X staining. Scale bar = 500 μm. 
FIGURE 10 Gene expression analysis of MMP13, collagen type I, collagen type II and collagen 
type X relativized to PSMB4, REEP5 and VPS29 and normalized to day 0 of MSC aggregates on 
day 1, 14 and 28 of cell culture under chondrogenic conditions analyzed by real time PCR. 
MMP13 and collagen type I gene expression show no significant differences between any time points. 
Collagen type II and X expression is statistically significantly upregulated from day 14 to day 28. n=3 
different donors. 
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4.1.2 Effect of hypertrophy enhancing medium conditions on MSC aggregates  
 
4.1.2.1 Histological analysis  
 
Under chondrogenic conditions aggregates on day 28 showed a homogenous 
morphology consisting of small, round cells that are surrounded by a uniform ECM very 
similar to hyaline cartilage structure. In comparison MSCs under hypertrophy 
enhancing conditions especially in the outer zone of the aggregates showed a distinct 
increase of cell volume and large intracellular lacunae, which are typical characteristics 
of hypertrophic cartilage. DMMB staining and immunohistochemical staining for 
collagen type II are strong in chondrogenic (Figure 11 B+C) as well as hypertrophic 
MSC aggregates (Figure 11 F+G). However, these two stainings are at least well suited 
to demonstrate the differences in morphology. Collagen type X staining, which is a 
marker for hypertrophy, showed distinct differences between chondrogenic and 
hypertrophic groups. While chondrogenic aggregates (Figure 11 D) featured only a 
slight staining, collage type X was clearly increased under hypertrophic conditions 
(Figure 11 H) particularly in the periphery of the aggregates. ALP staining (blue) was 
strong in hypertrophic areas and at the edge of the hypertrophic aggregates (Figure 
11 E) but limited to a thin frame around the aggregates under chondrogenic conditions 
(Figure 11 A). Unfortunately, the counterstaining with neutral red was very strong so 
that it may cover the blue ALP staining in a certain way, but at a closer look the blue 
staining in and around the hypertrophic cells was clearly visible (Figure 12 B). 
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4.1.2.2 Gene expression analysis 
 
To compare chondrogenic and hypertrophic aggregates on gene level we investigated 
the gene expression of the chondrogenic marker collagen type II, the hypertrophic 
markers collagen type X and MMP13 and the osteogenic marker collagen type I by 
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real time PCR analysis. Similar to the histological results collagen type II expression 
was equal in chondrogenic and hypertrophic conditions (FIGURE 13 B). As well as in 
collagen type I expression (FIGURE 13 A) no significant differences could be detected. 
Gene expression of COL1A1 was on a very low level throughout every time point and 
medium condition, which actually is an expected result and conformable to several 
other studies [135]–[137] that showed that collagen type I expression is high in 
undifferentiated mesenchymal cells and rapidly decreases in a very early stage of 
chondrogenic differentiation, which means immediately after transfer of the cells into 
the differentiation culture. Collagen type I gene expression stays down-regulated 
during chondrogenesis until final hypertrophic maturation stages.  
In contrast to immunohistochemical staining for collagen type X no statistically 
significant differences in collagen type X expression could be found between 
chondrogenic and hypertrophic aggregates (FIGURE 13 B). Merely gene expression 
analysis of the hypertrophic marker MMP13, which is involved in degradation of 
cartilage ECM proteins, revealed statistically significant differences between 
chondrogenic and hypertrophic groups (FIGURE 13 A). Aggregates that were kept 
under hypertrophy enhancing conditions expressed a higher level of MMP13 compared 
to chondrogenic MSC pellets.	 
 
 
 
FIGURE 13 Gene expression analysis of MMP13, COL1A1, COL2A1 and COL10A1 relativized to 
PSMB4, REEP5 and VPS29 and normalized to day 0 of chondrogenic and hypertrophic MSC 
aggregates analyzed by real time PCR. Collagen type I (A), collagen type II (B) and collagen type X 
(B) expression show no statistically significant differences between chondrogenic and hypertrophic 
groups. MMP13 expression (A) is statistically significantly upregulated under hypertrophy enhancing 
conditions compared to chondrogenic conditions. n=3 different donors. 
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4.2 Attenuation of hypertrophy upon treatment with BMS493  
 
As the RAR pathway plays a key role in growth plate hypertrophy, we aimed to 
investigate in this experiment weather inhibition of RAR signaling by treatment of 
chondrogenically differentiating MSCs with the RAR inverse agonist BMS493 may 
have influence on chondrogenesis and especially on hypertrophy in MSCs.  
 
4.2.1 Histological analysis 
 
Under chondrogenic conditions with continuous application of TGFb BMS treatment 
had small, but histologically visible effect on chondrocytes phenotype compared to 
chondrogenic control aggregates. Both groups showed a hyaline cartilage-like 
morphology with little indication of hypertrophy. Aggregates with BMS treatment were 
free of ALP positive cells (FIGURE 14 B) while chondrogenic control aggregates 
exhibited ALP staining in their outer zone (FIGURE 14 A). DMMB staining was a bit 
stronger in the BMS group (FIGURE 14 F). In immunohistochemistry chondrogenic 
aggregates with BMS treatment showed a higher content of collagen type II (FIGURE 
14 K), which is an evidence for the pro-chondrogenic effect of BMS. Collagen type X 
staining in the chondrogenic BMS group was nearly equal to control aggregates, 
however more concentrated at the edge of BMS aggregates (FIGURE 14 O). Under 
TGFb free conditions after chondrogenic pre-differentiation long term chondrogenic 
differentiation just occurred to a smaller extent. The weak DMMB staining and neutral 
red counterstaining in ALP aggregates indicate a small content of sulfated GAGs. Apart 
from that, the ECM contains nearly no collagen type II (FIGURE 14 L) compared to the 
chondrogenic groups. The application of BMS had no positive impact on 
chondrogenesis, actually it seems to inhibit chondrogenesis in a certain way based on 
the weaker DMMB and collagen type II staining (FIGURE 14 H, M). Thus, these results 
disagree with the hypothesis, that BMS treatment allows a proper chondrogenesis in 
absence of TGFb.  
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FIGURE 14 Histological appearance of MSC aggregates on day 28 after BMS treatment under 
chondrogenic conditions respectively in absence of TGFβ1. A, E, I, N Chondrogenic control group 
(Chon+). B, F, K, O Test group with BMS treatment from day 14 (Chon+ w BMS). DMMB staining (E, 
F) and immunohistochemical collagen type II staining (I, K) are increased after BMS treatment 
compared to Chon+. ALP staining (A, B) is reduced to a level of no visible ALP activity. Collagen type 
X staining is slightly increased at the edge of the aggregates after BMS treatment. C, G, L, P 
Chondrogenic control groups without TGFβ1 (Chon-). D, H, M, Q Test conditions without TGFβ1 after 
BMS treatment (Chon- w BMS). DMMB staining (G, H) and Collagen type II staining (L, M) are reduced 
after BMS treatment compared to Chon-. Collagen type X staining (P, Q) under both conditions is 
undetectable. Some single spots of ALP activity are visible in the control aggregates (C), but there is 
no ALP staining at all in the BMS group (D). Scale bar = 500 μm 
	 44	
Under hypertrophic conditions attenuation of hypertrophy by BMS depended on the 
time point of application during pellet culture. DMMB staining of hypertrophic control 
aggregates demonstrated the very pronounced hypertrophic phenotype with big, 
ballooned cells. Application of BMS in the late phase of chondrogenesis didn’t cause 
any big morphological change, but hypertrophic cells were smaller than in the 
hypertrophic control group and were fewer at the center of the aggregate. However, 
there were distinct differences in the groups with early BMS treatment. Apart from 
single hypertrophic cells the aggregates had a very homogenous structure consisting 
of small chondrocytes and an ECM rich in GAGs.  
ALP staining after late BMS treatment was reduced in the center and the outer zone 
of aggregates but still strong in the intermediate layer (FIGURE 15 B). Early BMS 
application decreased ALP activity even more, although there was still some ALP 
staining at the edge of the aggregates (FIGURE 15 C). Collagen II staining was 
unexpected strong in hypertrophic groups (FIGURE 15 G), as it is actually a 
chondrogenic marker, which physiologically decreases in reverse order to collagen 
type X content. This phenomenon may be founded on the effect of BMP4 in the 
proliferation medium to enhance hypertrophy. We assume that BMP4 initially boosts 
the entire synthesis activity of the chondrogenically differentiated MSCs including 
production of chondrogenic markers. Collagen type II concentration would probably 
decrease upon longer term duration.  
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Immunostaining of the hypertrophic marker Collagen type X was strong in hypertrophic 
control groups and spread over almost the whole aggregate (FIGURE 15 K). In Groups 
with BMS treatment in the late phase of differentiation collagen type X staining was 
influenced slightly. It was focused on the edge of the aggregates and a little reduced 
in the center (FIGURE 15 L). However, in aggregates that had obtained BMS during 
the first two weeks of pellet culture collagen type X staining was reduced most showing 
just a slight grey color (FIGURE 15 M).   
 
 
 
FIGURE 15  
Histological 
appearance of MSC 
aggregates on day 28 
under hypertrophic 
conditions. A, D, G, K 
Hypertrophic control 
groups (Hyp). B, E, H, L 
Hypertrophic aggregates 
after BMS treatment in 
late phase of 
differentiation (Hyp w 
BMS). C, F, I, M 
Hypertrophic aggregates 
after BMS treatment in 
early phase of 
differentiation 
(BMS/Hyp). There are 
remarkable changes in 
ALP (A, B, C), DMMB 
(D, E, F), collagen type II 
(G, H, I) and collagen 
type X staining (K, L, M) 
after late BMS treatment 
concerning volume and 
number of hypertrophic 
cells as well as 
expansion of 
hypertrophic markers 
(ALP, collagen type X). 
Early BMS treatment (C, 
F, I, M) leads to even 
greater changes 
including fewest 
hypertrophic cells, 
collagen type X content 
and ALP activity among 
the three hypertrophic 
conditions. Scale bar = 
500 μm 
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4.2.2 Gene expression analysis 
 
To further investigate the effect of BMS493 treatment to MSCs chondrogenesis and 
hypertrophy we performed a gene expression analysis of the chondrogenic marker 
collagen type II, the hypertrophic markers collagen type X and MMP13 and the 
osteogenic marker collagen type I. Under chondrogenic conditions BMS treatment has 
no influence on the expression of MMP13 and collagen type X on day 28 compared to 
chondrogenic control groups. Equally there is no change in gene expression of the 
hypertrophic markers detected after BMS treatment in combination with withdrawal of 
TGFβ1. However, under hypertrophy enhancing conditions BMS treatment seams to 
decrease expression of MMP13 and collagen type X on day 28 especially after BMS 
application during early stage of differentiation (BMS/Hyp). Although there are no 
statistically significant differences between the hypertrophic groups probably based on 
the number of donors (n=3) gene expression of collagen type X in BMS/Hyp is on the 
same level as in the chondrogenic groups (Chon+, Chon+ BMS), which never the less 
is an indication for the pro-chondrogenic effect of BMS. Also, the differences in MMP13 
expression between the hypertrophic groups on day 28 are not statistically significant. 
But there are significant differences between the hypertrophic control group (Hyp) and 
the two chondrogenic groups (Chon+, Chon+ BMS) but no significant differences 
between the chondrogenic groups and the two BMS treated hypertrophic groups (Hyp 
BMS, BMS/Hyp). This means that BMS treatment under hypertrophic conditions 
downregulated MMP13 gene expression as far as the differences to chondrogenic 
groups are no longer significant. Similar to histological analysis gene expression of 
collagen type II is unexpected high in hypertrophic groups, what we, as previously 
explained, attribute to the impact of BMP4. However, collagen type II gene expression 
in hypertrophic aggregates with early BMS treatment (BMS/Hyp) is on the same level 
with gene expression in chondrogenic aggregates (Chon+, Chon+ BMS), which is a 
sign for the favorable effect of BMS on MSCs chondrogenesis and attenuation of the 
effect of BMP4. 
As expected, collagen type I expression is on the same low level under every condition 
and at every time point without significant differences. BMS treatment seems to have 
no regulating effect on collagen type I expression neither under chondrogenic nor 
hypertrophic conditions.   
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FIGURE 16  
Gene expression 
analysis of the 
chondrogenic 
marker  
collagen type II, 
the osteogenic 
marker collagen 
type I and the 
hypertrophic 
markers, collagen 
type X and 
MMP13, in MSC 
aggregates after 
BMS treatment 
under 
chondrogenic, 
TGFβ1 free and 
hypertrophy 
enhancing 
conditions on 
days 1, 14 and 28 
analyzed by real 
time PCR. 
normalized to day 
0. n = 3 different 
donors.  
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4.2.3 Biochemical analysis 
 
For biochemical analysis Sulfated GAG content of each pellet was determined and 
related to the DNA content as a quantitative differentiation marker. ALP activity in the 
medium supernatant was used as a quantitative marker for hypertrophy. 
 
4.2.3.1 GAG content  
 
DNA and GAG content were measured on day 1, day 14 and day 28. There was no 
significant difference in DNA content throughout all groups and time points (FIGURE 
17 A), which is a sign for an equal number of cells and no increased rate of cell division 
or apoptosis under particular conditions. However, there were significant differences 
in GAG content relativized to DNA on day 28 (FIGURE 17 B). For example, GAG 
content was significantly reduced after withdrawal of TGFb1 from day 14 of cell culture 
(Chon-) compared to the chondrogenic control group (Chon+). This shows similarly to 
histological and PCR results that chondral differentiation capacity of human MSCs is 
very low under TGFb1 free conditions and BMS treatment (Chon- BMS) is not capable 
of improving that loss. Under hypertrophy enhancing conditions BMS treatment in the 
early phase of differentiation (BMS/Hyp) significantly decreased GAG content 
compared to the group with late BMS treatment (Hyp BMS). As a sign for increased 
synthesis activity the high GAG content in the hypertrophic group similar to the high 
collagen type II gene expression can probably be traced back to the effect of BMP4.  
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4.2.3.2 ALP activity 
 
ALP activity analysis in medium supernatant on day 28 of MSC pellet culture revealed 
that ALP activity was significantly higher in hypertrophic control aggregates (FIGURE 
19 Hyp) compared to chondrogenic control aggregates (FIGURE 19 Chon+). These 
findings are in accordance with the histological results as alkaline phosphatase is a 
reliable biochemical marker for hypertrophy and in later stages for osteoblast activity. 
However, there are no significant differences in ALP activity between the chondrogenic 
control group and the hypertrophic groups treated with BMS, both early treatment 
group (FIGURE 19 BMS/Hyp) and late treatment group (FIGURE 19 Hyp w BMS). This 
means that BMS treatment under hypertrophy enhancing conditions independently 
from the time point of treatment had reduced ALP activity as far, that it is no longer 
significantly different from ALP activity under chondrogenic conditions. Thus, there is 
a distinct effect of BMS treatment to activity of the hypertrophic marker ALP.  
FIGURE 17         
Biochemical analysis 
of MSC aggregates on 
day 14 and day 28. 
Data are normalized 
to those of day 1. A 
DNA content. B GAG 
content relative to DNA 
content. DNA content is 
equal throughout all 
groups and time points. 
GAG content is 
significantly decreased 
under TGFb1 free 
conditions compared to 
chondrogenic control 
groups. Under 
hypertrophic conditions 
early BMS treatment 
effected a significant 
reduction in GAG 
content compared to 
the late BMS group. 
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FIGURE 18 Change of absorbance at 405nm in medium supernatant of day 28 MSC pellets over 
time. Graphs show the linear range of reaction. The gradients of the single graphs are directly 
proportional to the enzymatic activity in the associated groups. ALP activity is highest in 
hypertrophic groups and very low in chondrogenic groups. There is nearly no ALP activity under TGFb1 
free conditions. n = 3 
FIGURE 19 ALP activity in the medium supernatant of day 28 MSC pellets. ALP activity is 
significantly increased in the hypertrophic control group (Hyp) compared to the chondrogenic control 
group (Chon+). But there are no significant differences in ALP activity between the BMS treated 
hypertrophic groups and the chondrogenic control group. Thus, BMS treatment under hypertrophic 
conditions had reduced ALP activity as far as it is no longer significant higher to ALP activity under 
chondrogenic conditions. n = 3 
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5 Discussion 
 
During skeletal development retinoids are important regulators of growth plate 
chondrogenesis [70], [71], [138]. RAR signaling is supposed to inhibit differentiation of 
pre-chondrogenic cells into chondroblasts [57], [58] and to promote chondrocyte 
maturation during endochondral ossification [56]. Thus, inhibition of RAR signaling with 
specific retinoid antagonists in order to suppress hypertrophic conversion and 
therefore support chondrogenic differentiation seems to be a promising way to solve 
current problems of in vitro MSC chondrogenesis. Nevertheless, retinoid acid signaling 
is complex and accompanied with several downstream pathways, which are 
modulating and mediating retinoid effects and have to be considered in conclusions 
about the potential effect of RAR antagonism.  
In this study we investigated whether the modulation of the RAR pathway with a pan-
RAR inverse agonist is capable of promoting or even inducing chondrogenesis of 
human MSCs in vitro. We used standard long term chondrogenic pellet culture to 
investigate the effect of the synthetic RAR inverse agonist BMS493 on 
chondrogenesis, matrix synthesis and cell phenotype of human MSCs in vitro. 
Additionally, we employed an established hypertrophy inducing media condition in 
order to unveil anti-hypertrophic influence of BMS493. Our data show that BMS is a 
promising attenuator of MSC hypertrophy and can promote TGFb induced 
differentiation. However, BMS cannot replace TGFb in a pro-chondrogenic 
environment.  
BMS decreased expression, production and activity of hypertrophy related proteins 
such as MMP13, collagen type X and ALP. Interestingly, markers related to stable 
hyaline cartilage like collagen type II and glycosaminoglycans were also down-
regulated by BMS under hypertrophic conditions. However, chondrogenic markers 
were less influenced by BMS than hypertrophic markers.  
We chose in vitro pellet culture to study the influence of retinoid inhibition on 
chondrogenic differentiation of MSCs. Pellet culture is a suitable system for our 
purpose as it is not impaired by undefined soluble compounds and mimics the three-
dimensional cell-cell contact. This biochemical interplay allows for improved cartilage 
formation as already shown by multiple working [35], [36], [39], [40]. Crucially, the 
serum-free differentiation medium is especially free of retinoids. Neither the 
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chondrogenic medium nor the hypertrophic medium contains any retinoids or precursor 
molecules, and mammalian cells are incapable of de novo retinoid synthesis [139]. 
On the other hand, this model does not represent the physiological situation during 
limp development that is characterized by the influence of retinoic acid especially in 
the late stage of chondrocyte maturation, when vessels spread into the cartilage 
template. In our study design tRA lacks as a competitive rival for BMS at RAR as we 
focus on the unimpaired effect of BMS. The presence of the full RAR agonist might 
interfere or at least diminish the BMS effect. Unliganded RAR acts pro-
chondrogenically by basal repression of target gene transcription [73] and inverse 
agonists like BMS are capable of further reducing basal receptor activity in the absence 
of the physiological agonist [82].  
 
5.1 Differentiation of MSC aggregates under chondrogenic and 
hypertrophy enhancing conditions 
 
As MSCs are multipotent cells they are able to differentiate into a range of different 
mesenchymal tissues including cartilage. Though in vitro chondrogenically 
differentiating MSCs tend to undergo hypertrophy characterized by an increased cell 
size and expression of hypertrophic markers. The hypertrophic phenotype of 
chondrogenic differentiation can be significantly enhanced by special hypertrophy 
inducing medium containing BMP4 as described previously  [42], [44]. To illustrate the 
anti-hypertrophic effect of BMS493 we used this hypertrophy enhancing model besides 
the standard chondrogenesis model, which includes addition of TGFb1 and 
dexamethasone instead of BMP4. The rise of hypertrophy was clearly demonstrated 
by increased volume and swollen appearance of the chondrocytes, stronger ALP and 
collagen type X staining and higher expression of MMP13 in hypertrophic MSC 
aggregates. But also aggregates that were kept under chondrogenic conditions 
exhibited hypertrophic characteristics even though to a lower degree. 
ALP staining was strong in hypertrophic MSC pellets but limited to small isolated spots 
and a thin ring around the aggregates under chondrogenic conditions. As described 
by Yoo et al there is a layer of flattened fibroblast like cells around the aggregates that 
did not differentiate chondrogenically and form a structure similar to the perichondrium 
[36]. Thus, we assume that the ALP positive frame around the chondrogenic MSC 
pellets more likely consists of fibroblast like cells than of hypertrophic chondrocytes. 
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Next to the histological findings ALP activity analysis exhibited clear results. ALP 
activity in the medium supernatant was significantly increased under hypertrophic 
conditions compared to chondrogenic control aggregates. 
Collagen type X staining showed distinct differences between chondrogenic and 
hypertrophic groups. While chondrogenic aggregates featured only a slight staining, 
collage type X was clearly increased under hypertrophic conditions. However, in 
opposition to the histological findings there were no significant differences in collagen 
type X gene expression. This has been described in several other studies [40], [140], 
[141].	One possible explanation may be that post-transcriptional modulations effect 
these differences in final protein synthesis, which can be seen in immunohistochemical 
staining. On the other hand, gene expression of collagen type X might already have 
been decreased at this stage of hypertrophic conversion, while collagen type X protein 
is still traceable. 
We investigated collagen type II gene expression and synthesis, as it is a typical 
chondrogenic marker, which physiologically decreases in inverse proportion to 
collagen type X content. But there were no statistically significant differences between 
chondrogenic and hypertrophic groups in collagen type II gene expression. 
Immunohistochemical collagen type II staining was strong under chondrogenic 
conditions as well as hypertrophy enhancing conditions. And collagen type II gene 
expression even tended to be higher in hypertrophic aggregates compared to 
chondrogenic control groups. 
These unexpected findings in hypertrophic groups may be founded on the effect of 
BMP4 in the proliferation medium to enhance hypertrophy. We assume that BMP4 
initially boosts the entire synthesis activity of the chondrocytes including production of 
chondrogenic markers. BMP4 as a bone-inductive protein is involved in chondrocyte 
hypertrophy and matrix degradation but there is also evidence for BMP4 to stimulate 
chondrogenic differentiation and cartilage ECM synthesis in an earlier step of 
chondrogenesis including expression of collagen type II [113]. Collagen type II 
expression and concentration would probably decrease in progress of further 
hypertrophic differentiation.  
Only PCR analysis of the hypertrophic marker MMP13, which is involved in 
degradation of cartilage ECM proteins, revealed a significant higher gene expression 
level in hypertrophic groups compared to chondrogenic groups. 
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In summary we successfully enhanced the hypertrophy of chondrogenically 
differentiating MSCs by changing medium conditions, which was demonstrated by the 
histological phenotype, increased ALP activity and higher MMP13 gene expression. 
But we detected an unexpected high level of the chondrogenic marker collagen type II 
under BMP4 treatment. This factor has to be considered in the interpretation of our 
further results. 
 
5.2 Attenuation of hypertrophy upon treatment with BMS493  
 
Retinoid signaling plays a key role in chondrocytes maturation during limb 
skeletogenesis. As retinoids induce hypertrophy and mineralization and attenuate 
chondrogenic differentiation we assumed that inhibition of the RAR pathway by 
treatment with the RAR inverse agonist BMS493 would decrease or even prevent 
hypertrophy in chondrogenically differentiating MSCs. To investigate the effect of BMS 
treatment under different conditions we used a hypertrophy enhancing cell culture 
model as well as a standard in vitro chondrogenesis model with established 
chondrogenic medium containing TGFb1. Additionally, we launched a test series under 
TGFb1 free conditions. Under hypertrophy enhancing conditions BMS was applied 
during two different periods. One group obtained BMS during the early phase of 
chondrogenesis and a second one during the late phase. 
 
5.2.1 BMS treatment under TGFb1 free conditions  
 
Our results indicate that MSCs did not fulfill an adequate chondrogenic differentiation 
under TGFb1 free conditions. Collagen type II staining in TGFb1 free aggregates was 
very weak compared to chondrogenic groups treated with TGFb1 and collagen type X 
staining was not detectable at all. The weak DMMB staining and neutral red 
counterstaining in ALP aggregates indicate a small content of sulfated GAGs, which 
was supported by biochemical analysis. GAG content was significantly reduced after 
withdrawal of TGFb1 compared to the chondrogenic control group. Thus, ECM 
synthesized in TGFb1 free MSC pellets did not feature typical characteristics of 
cartilage ECM including high content of aggrecan and collagen type II. 
The application of BMS after withdrawal of TGFb1 had no positive impact on 
chondrogenesis, actually it seemed to inhibit chondrogenesis in a certain way based 
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on the weaker DMMB and collagen type II staining compared to the TGFb1 free control 
group. BMS treatment did not effect a statistically significant increase in GAG content. 
Thus, these results disagree with the hypothesis, that BMS treatment allows a proper 
chondrogenesis in absence of TGFb, and thereby don’t support the findings of Wael 
et al. who showed induction of chondrogenic differentiation in hMSCs by treatment with 
an RAR antagonist in absence of growth factors [142]. 
 
5.2.2 BMS treatment under chondrogenic conditions 
 
Histological analysis revealed some differences between chondrogenic control groups 
and BMS treated test groups. 
MSC aggregates treated with BMS were free of ALP positive cells, whereas 
chondrogenic control aggregates exhibited ALP staining in their outer zone. 
DMMB staining was a bit stronger in the BMS group, which is a sign for a higher content 
of GAGs in the ECM. And chondrogenic aggregates with BMS treatment showed a 
higher content of collagen type II compared to chondrogenic control groups. These 
histological findings are evidence for the pro-chondrogenic effect of BMS. However, 
biochemical and gene expression analysis did not show significant differences 
between BMS treated aggregates and control aggregates under chondrogenic 
conditions. 
In summary, effects of BMS treatment on hypertrophy under chondrogenic conditions 
were little and restricted to the histological level because the hypertrophic phenotype 
in this phase of differentiation has not been strong enough yet to allow great 
differences. This leads us to our most relevant groups. Under hypertrophic conditions 
we were able to achieve a distinct attenuation of hypertrophy by BMS treatment. 
 
5.2.3 BMS treatment under hypertrophy enhancing conditions 
 
The efficiency of BMS treatment under hypertrophic conditions was dependent on the 
time point of application in pellet culture. Starting with the histological morphology BMS 
treatment in the late phase of chondrogenesis only produced little reduction in volume 
and number of hypertrophic cells whereas the group with early BMS treatment showed 
distinct morphological differences. Apart from single hypertrophic cells the aggregates 
had a very homogenous structure consisting of small chondrocytes. Staining of the 
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hypertrophic markers, ALP and collagen type X, was reduced in both, early and late 
BMS treatment groups. 
However, aggregates that had obtained BMS during the first two weeks of pellet culture 
showed the best histological results.  
Collagen type II staining and gene expression was on an unexpected high level in 
hypertrophic groups, what we as previously explained attribute to the impact of BMP4. 
However, collagen type II gene expression in hypertrophic aggregates with early BMS 
treatment is down-regulated to the same level as gene expression in chondrogenic 
aggregates, which may be a sign for the pro-chondrogenic effect of BMS on MSCs and 
the potential attenuation of the effect of BMP4 under BMS treatment. Several studies 
from different medical fields indicate that RAR and BMP signaling are closely 
associated and cooperate on various levels: Apart from direct retinoid effects on 
chondrocyte maturation through activation of RARs, retinoic acid furthermore seems 
to stimulate genes encoding BMPs, which leads to an indirect induction of collagen 
type X expression in pre-hypertrophic chondrocytes [143], [144]. Leaving the field of 
orthopedics, BMP and RA reveal more synergistic effects. Within oncology retinoids 
are clinically used in therapy of epithelial cancer and promyelocytic leukemia to initiate 
apoptosis in tumor cells [145], [146]. Müller et al. recently showed that retinoic acid 
and BMP synergistically induce apoptosis in retinoblastoma cell lines. BMP4 treatment 
increased the gene expression of specific RAR and RXR subtypes [147]. With regard 
to these enhancing interactions between the RAR and the BMP pathway it appears 
reasonable that inhibition of RAR signaling with BMS has negative influence on BMP4 
effects. 
Gene expression of the hypertrophic markers MMP13 and collagen type X was 
reduced by BMS treatment especially by BMS application in the early stage of 
differentiation.  
Biochemical analysis revealed a statistically significant difference between early BMS 
treatment and late BMS treatment under hypertrophy enhancing conditions. BMS 
treatment in the early phase of differentiation significantly decreased GAG content 
compared to the group with late BMS treatment.  
As a sign for increased synthesis activity the high GAG content in hypertrophic group 
similar to the high collagen type II gene expression can be probably traced back to the 
effect of BMP4. Consequently, the significant reduction of GAG content under BMS 
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treatment in early phase of differentiation may demonstrate an attenuation of this BMP 
effect by BMS. 
We found statistically significantly higher ALP activity in the hypertrophic control group 
compared to the chondrogenic control group. But BMS treatment in both, early and 
late phase of differentiation, reduced ALP activity under hypertrophy enhancing 
conditions down to the range of the chondrogenic groups.  
 
Although in vitro results are promising there will be some limitations for the in vivo use 
of BMS. Indeed, retinoids are clinically used for a number of therapeutic indications 
including cancer, psoriasis, acne and diabetes but they can lead to severe side effects 
especially through systemic application. Thus, the topical application by intraarticular 
injection would be favorable. For the therapy of osteoarthritis, Yin et al. developed a 
drug delivery system especially for BMS using an engineered cartilage oligomeric 
matrix protein coiled-coil protein to encapsulate and protect the hydrophobic and 
unstable BMS molecule [148]. 
Furthermore, there are novel, atypical drugs that might be an alternative to BMS in 
vivo. Busby et al. presented the first non-acid, non-retinoid direct modulator of the RAR 
superfamily that acts as a pan-RAR inverse agonist like BMS but features an improved 
toxicity and pharmacokinetic profile over classical retinoids [149]. However, their 
efficiency in chondrogenesis protocols has to be further investigated. 
 
In this study, we validated that chondrogenically differentiated human MSCs in 3D 
aggregate can produce features of hypertrophic conversion. Hypertrophic media 
challenge furthermore enhances hypertrophy. However, inclusion of the RAR inverse 
agonist BMS attenuated these hypertrophic changes, which may be useful in 
producing stable engineered tissue for cartilage regeneration. Specifically, when BMS 
was administered under hypertrophic conditions, a decrease in cell size, ALP activity 
and gene expression of hypertrophic markers could be observed. Our experiments 
revealed the early phase of chondrogenesis as the best period for the application of 
BMS in order to attenuate hypertrophy. Based on these findings, current studies are 
exploring the dose of BMS to most efficaciously prevent hypertrophic changes, as well 
as the duration of its effect and delivery in a therapeutic setting. Further, we are 
investigating the pathways through which BMS493 exerts its effects. 
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6 Conclusion 
 
In our study we demonstrated that inclusion of the RAR inverse agonist BMS493 during 
in vitro chondrogenesis of hMSCs can attenuate hypertrophic changes, which may be 
useful in producing stable engineered tissue for cartilage regeneration. Specifically, 
when BMS was administered under hypertrophic conditions, a decrease in cell size, 
ALP activity and gene expression of hypertrophic markers is observed. Our 
experiments reveal the early phase of chondrogenesis as the best period for the 
application of BMS in order to attenuate hypertrophy. Moreover, our findings indicate 
that the chondrogenic effect of BMS is dependent on the presence of TGFb1 and that 
BMS exerts its’ effect at least partially through interaction with BMP signaling. Thus, 
there are several connections between BMP and the TGFb-Superfamily. However, 
their exact relationship during chondrogenesis deserves further investigation.  
Beside the very convincing histological outcome our results hardly reached statistical 
significance due to the low number of donors, even if there is a clearly visible tendency 
regarding the pro-chondrogenic effect of BMS. Further studies are planned to confirm 
the current results.  
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